(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 8.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Immunocore Holdings's revenue in 2024 is $295,836,750.On average, 6 Wall Street analysts forecast IMCR's revenue for 2024 to be $15,504,204,800, with the lowest IMCR revenue forecast at $15,428,605,285, and the highest IMCR revenue forecast at $15,685,273,395. On average, 6 Wall Street analysts forecast IMCR's revenue for 2025 to be $17,391,991,245, with the lowest IMCR revenue forecast at $15,952,298,288, and the highest IMCR revenue forecast at $18,947,409,999.
In 2026, IMCR is forecast to generate $18,665,375,275 in revenue, with the lowest revenue forecast at $16,660,512,148 and the highest revenue forecast at $20,683,547,118.